Gain Therapeutics Inc (GANX NASDAQ) stock market data APIs
$1.7562
0.03(1.7%)
as of July 10, 2025
Try our APIs with
free plan!
Gain Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Prev. Close
1.7562
Open
1.7854
High
1.844
Low
1.7224
52 wk Range
0.89-3.19
Market Cap
53 004 K
Shares Outstanding
29 946 K
EPS
-0.16
Beta
0.112
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gain Therapeutics Inc data using free add-ons & libraries
Get Gain Therapeutics Inc Fundamental Data
Gain Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -20 314 820
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gain Therapeutics Inc News
New
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations
Investing.com - Gain Therapeutics (NASDAQ:GANX), a clinical-stage biotech company with a market cap of $48.3 million, announced accelerated enrollment in its Phase 1b clinical study evaluating GT-02...
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid ...
Gain Therapeutics increases authorized common shares to 100 million after stockholder vote
Gain Therapeutics , Inc. (NASDAQ:GANX) announced Tuesday that it has amended its certificate of incorporation to increase the number of authorized shares of its common stock from 50 million to 100 mil...
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and developmen...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
